...BRCA2/ATM/CDKN2A/STK11/PALB2/TP53, as well as mismatch repair genes, confer a substantially higher lifetime risk, while ...
...BRCA2 are the predominant genetic contributor, conferring a lifetime risk of ~7%, while BRCA1, CHEK2 and PALB2 variants ...
...BRCA2. This study demonstrates poor facility-level adherence with MSI/MMR testing recommendations and poor patient-level...
...BRCA2 mutant tumors. USP1 is a deubiquitylating enzyme responsible for the removal of the mono-ubiquitin mark on FANCD2,...
...BRCA2, CDH1, CHEK2, EPCAM, PALB2, and PMS2 are more strongly associated with ILC - to varying degrees. [p < 0.001]. Addi...
...BRCA2 as potential drivers. These alterations were clonally concordant with circulating tumor DNA from the donor. Pathwa...
...BRCA2 genes. Throughout the clinical course, the patient exhibited discordant results for HER2 in immunohistochemistry a...
...BRCA2, may be enriched in urothelial cancer and have important cascade testing implications for families, regardless of ...
...BRCA2-mutant pancreatic cancer cell line), we evaluated the combinatorial effects of olaparib, a PARP inhibitor, and oxa...
...BRCA2, ATM, RAD50, ERCC4, RPA1, MLHI, and ATR genes. Somatic mutations of TP53 were found in nine cases (90%) and were t...
Contact
No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong
Qilu Normal University · Genelibs Bioinformatics Lab
750 Shunhua Rd, Jinan
2F, Bldg F, University Science Park
Tel: 0531-88819269
WeChat Official Account
Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.
Business Email
E-mail: product@genelibs.com
Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2
